Literature DB >> 1547776

Specific binding of a basic peptide from HIV-1 Rev.

J Kjems1, B J Calnan, A D Frankel, P A Sharp.   

Abstract

Human immunodeficiency virus type I (HIV-1) encodes a regulatory protein, Rev, which is required for cytoplasmic expression of incompletely spliced viral mRNA. Rev activity is mediated through specific binding to a cis-acting Rev responsive element (RRE) located within the env region of HIV-1. A monomer Rev binding site corresponding to 37 nucleotides of the RRE (IIB RNA) was studied by RNA footprinting, modification interference experiments and mutational analysis. Surprisingly, a 17 amino acid peptide, corresponding to the basic domain of Rev, binds specifically to this site at essentially identical nucleotides and probably induces additional base pairing. The Rev protein and related peptide interact primarily with two sets of nucleotides located at the junction of single and double stranded regions, and at an additional site located within a helix. This suggests that the domains of proteins responsible for specific RNA binding can be remarkably small and that the interaction between RNA and protein can probably induce structure in both constituents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1547776      PMCID: PMC556554          DOI: 10.1002/j.1460-2075.1992.tb05152.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  36 in total

1.  Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure.

Authors:  S M Holland; N Ahmad; R K Maitra; P Wingfield; S Venkatesan
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Regulation by HIV Rev depends upon recognition of splice sites.

Authors:  D D Chang; P A Sharp
Journal:  Cell       Date:  1989-12-01       Impact factor: 41.582

Review 3.  Regulatory pathways governing HIV-1 replication.

Authors:  B R Cullen; W C Greene
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

4.  Synthesis of small RNAs using T7 RNA polymerase.

Authors:  J F Milligan; O C Uhlenbeck
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

5.  Sequence-specific recognition of RNA hairpins by bacteriophage antiterminators requires a conserved arginine-rich motif.

Authors:  D Lazinski; E Grzadzielska; A Das
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

6.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

7.  The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization.

Authors:  M Emerman; R Vazeux; K Peden
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

8.  Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus.

Authors:  C A Rosen; E Terwilliger; A Dayton; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

9.  HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence.

Authors:  M H Malim; L S Tiley; D F McCarn; J R Rusche; J Hauber; B R Cullen
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

10.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

View more
  69 in total

1.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Bamboo mosaic potexvirus satellite RNA (satBaMV RNA)-encoded P20 protein preferentially binds to satBaMV RNA.

Authors:  M S Tsai; Y H Hsu; N S Lin
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  In vitro selection of ribozymes dependent on peptides for activity.

Authors:  Michael P Robertson; Scott M Knudsen; Andrew D Ellington
Journal:  RNA       Date:  2004-01       Impact factor: 4.942

4.  Sindbis virus nucleocapsid assembly: RNA folding promotes capsid protein dimerization.

Authors:  Benjamin R Linger; Lyudmyla Kunovska; Richard J Kuhn; Barbara L Golden
Journal:  RNA       Date:  2004-01       Impact factor: 4.942

5.  Spatial determinants of the alfalfa mosaic virus coat protein binding site.

Authors:  Siana M Laforest; Lee Gehrke
Journal:  RNA       Date:  2004-01       Impact factor: 4.942

6.  Selection of RRE RNA binding peptides using a kanamycin antitermination assay.

Authors:  Hadas Peled-Zehavi; Satoru Horiya; Chandreyee Das; Kazuo Harada; Alan D Frankel
Journal:  RNA       Date:  2003-02       Impact factor: 4.942

7.  Stereospecificity of short Rev-derived peptide interactions with RRE IIB RNA.

Authors:  Alexander Litovchick; Robert R Rando
Journal:  RNA       Date:  2003-08       Impact factor: 4.942

8.  Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/MS2 fusion protein which tethers the MS2 operator RNA.

Authors:  S Venkatesan; S M Gerstberger; H Park; S M Holland; Y Nam
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element.

Authors:  H P Bogerd; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 10.  Fluorescent indicator displacement assays to identify and characterize small molecule interactions with RNA.

Authors:  Sarah L Wicks; Amanda E Hargrove
Journal:  Methods       Date:  2019-04-30       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.